Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Australian Pancreatic Cancer Genome Initiative

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5093990436. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 2 papers

Papers 11

  1. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  2. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  3. MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. Co-author DOI 10.1016/j.neo.2025.101138↗
  4. Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03051-z↗
  5. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  6. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  7. Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Co-author DOI 10.1016/j.biomaterials.2019.119742↗
  8. Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Co-author DOI 10.1186/s40170-017-0164-1↗
  9. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2013.722↗
  10. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  11. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1202490109↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amber L. Johns · 4 shared papers, 2014–2026 · strength 0.56
  2. Anthony James Gill · 4 shared papers, 2014–2026 · strength 0.56
  3. David Goldstein · 3 shared papers, 2020–2026 · strength 0.50
  4. Joshua A. McCarroll · 3 shared papers, 2020–2026 · strength 0.50
  5. Phoebe A. Phillips · 3 shared papers, 2020–2026 · strength 0.50
  6. George Sharbeen · 3 shared papers, 2020–2026 · strength 0.50
  7. John Kokkinos · 3 shared papers, 2020–2026 · strength 0.50
  8. Marina Pajic · 4 shared papers, 2014–2026 · strength 0.47
  9. Andrew Victor Biankin · 5 shared papers, 2012–2025 · strength 0.47
  10. David Kuang-Fu Chang · 4 shared papers, 2012–2025 · strength 0.42
  11. Mert Erkan · 2 shared papers, 2025–2026 · strength 0.39
  12. Koroush Shahsavar Haghighi · 2 shared papers, 2025–2026 · strength 0.39
  13. Stephan B. Dreyer · 2 shared papers, 2023–2025 · strength 0.36
  14. Katharine J. Herbert · 1 shared paper, 2025 · strength 0.23
  15. Fieke E. M. Froeling · 1 shared paper, 2025 · strength 0.23
  16. Christian P. Pilarsky · 1 shared paper, 2025 · strength 0.23
  17. Val Gebski · 1 shared paper, 2026 · strength 0.20
  18. Jennifer P. Morton · 1 shared paper, 2026 · strength 0.20
  19. James Ephraums · 1 shared paper, 2025 · strength 0.19
  20. Jaswinder Singh Samra · 2 shared papers, 2014–2023 · strength 0.17
  21. Alessandra Pulvirenti · 1 shared paper, 2023 · strength 0.13
  22. Antonio Pea · 1 shared paper, 2023 · strength 0.13
  23. Georgios Gemenetzis · 1 shared paper, 2023 · strength 0.13
  24. Alessandro Zerbi · 1 shared paper, 2023 · strength 0.13
  25. Nigel Balfour Jamieson · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.